There are just two days left to secure your place to hear our fantastic Antibody Validation speakers in September 2018.
In its third edition, this event is a highlight in the antibody calendar and brings together scientists from academia, the pharmaceutical/biotech sector and antibody suppliers in order to discuss best practices in research antibody validation and help improve antibody validation for the life science community.
This year our international panel of speakers includes:
Birte Aggeler, Bio-Techne (R&D Systems) from the USA
Birte is Director of Antibody Development and Flow Cytometry at Bio-Techne (R&D Systems), who holds a Doctor of Philosophy focused in Biochemistry and Molecular Biology from Johann Wolfgang Goethe-Universität Frankfurt am Main. Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities.
Dagmar Ehrnhoefer, BioMed X from Germany
Dr Ehrnhoefer studies tau pathology in Alzheimer’s disease, and is particularly interested in tau post-translational modifications. Since antibodies against modified tau are poorly characterized, the lab has validated a panel of these tools to improve data quality and reproducibility and raise awareness for the issue.
Richard Goodwin, AstraZeneca from the UK
Richard Goodwin is a Principal Scientist leading the mass spectrometry imaging group within Drug Safety and Metabolism (DSM) at AstraZeneca. His interests focus on the use of current and emerging MS imaging technologies for the analysis of drug bio-distributions, efficacy and investigatory toxicity.
Jason Li, Proteintech from the USA
Jason Li, Ph.D., founded Proteintech Group with fellow scientists in 2002. Their goal: provide researchers a reliable, reproducible antibody for every human protein. Proteintech manufactures all antibodies in-house, with an emphasis on developing antibodies from whole proteins.
Deepa Shankar, Thermo Fisher from the USA
Deepa is Director for Research and Development of Immunoreagents and Immunoassays at the Life Sciences Group division of Thermo Fisher Scientific. She has been with ThermoFisher Scientific for the past seven years, utilising her expertise in molecular immunology to develop recombinant antibody platforms and Immunoassays.
Mathias Uhlén, Royal Institute of Technology from Sweden
Mathias received his PhD at the Royal Institute of Technology, Stockholm, Sweden in 1984. After a post-doc period at the EMBL in Heidelberg, Germany, he became professor in microbiology at KTH in 1988. His research is focused on protein science, antibody engineering and precision medicine and ranges from basic research in human and microbial biology to more applied research, including clinical applications in cancer, infectious diseases, cardiovascular diseases, autoimmune diseases and neurobiology.
Gemma Jones, AstraZeneca from the UK
Gemma Jones is a Senior Scientist in Translational Sciences at AstraZeneca, working within the Oncology division to support projects targeting DNA damage response (DDR) pathways. She develops and implements IHC assays, as well as performing digital image analysis.
Roberto Polakiewicz, Cell Signaling Technology from the USA
Roberto D. Polakiewicz is the CSO of Cell Signaling Technology (CST) and is in charge of R&D and technology innovation. Over the years Roberto has been responsible for the creation and implementation of novel antibody technology and validation platforms that have been critical to CST’s success.
Jan Roger, GlaxoSmithKline from the UK
Jan is a scientific manager specialising in cell and tissue-based target identification, selection and validation, particularly focussed on the use of human samples. He also has a strong interest in driving laboratory workflow efficiency, and software usability improvement.
Kathryn Lilley, University of Cambridge in the UK
Kathryn Lilley is a Professor in the Department of Biochemistry and the Cambridge Systems Biology Centre. She is also Director of the Cambridge Centre for Proteomics, and a Director of Studies at Jesus College. Kathryn’s research specialises in the development of cutting edge proteomics technologies.
Alejandra Solache, Abcam from the UK
Alejandra is responsible for managing the output of Abcam’s Global New Product Development and Validation efforts of our teams in Cambridge, Hangzhou, Eugene and Branford, CT. She also plays a key role in developing Abcam’s innovation strategy.
Dr Andrew Chalmers, founder of CiteAb, says: “This year we have a truely inspirational speaker panel and I hope that you’re able to join us in Bath in September to hear them in action. You can still sign up for a few more days – and if you have any questions at all about the event do get in touch with the team here at CiteAb and they’ll be happy to help.”
Read more about the event and sign up here: http://www.antibodyvalidation.co.uk/
Have you already signed up to join us in September? Join our Facebook event page now to network with others attending. https://www.facebook.com/events/460763191061955/?active_tab=about
The team behind the organising of this years’ event would like to give a big shout out to sponsors:
Abcam, Atlas Antibodies, GeneTex, Proteintech, BioTechne R&D Systems, ThermoFisher Scientific, Miltenyi Biotech, Progen and Ximbio.
Without the support of these organisations, it would not be possible to run this valuable event.